Transaction · 0001213900-26-098030

Shen Ethan PhD

Shen Ethan PhD, CEO, reported an open-market or private purchase at YD Bio Ltd involving 18378.000000 shares for an estimated $67447.26. Reported holdings after the transaction were 11242531.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

Open-market buySEC transaction code PCEO
YDESYD Bio Ltd
Filing timeSep 08
Trade dateSep 04, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
—
Pre-filing
1mo ago1w ago1d ago
Returns since
7d30d90d180d1y

YDES price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
YDES since 2026-09-08Filed yesterday · 1 day of post-filing data
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Buy
Code P
Identifier
0001213900-26-098030
Ordinary Shares
Transaction date
Sep 04, 2026
Filed Sep 08, 2026, 08:00 PM · 4d delay
Shares
18.3k sh
$367 per share
Estimated value
$6.74M
Computed from shares × price
Holdings after
11.2M sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
CEO Buy Director Buy Direct Ownership
+30score
Filing-only score

+30

Compact filing score computed from stored Form 4 facts. Version v1.

Strong filing signal

This filing has a high positive filing-only score. It may deserve closer research, but it is not an investment recommendation.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

CEO

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.50 to $3.70, inclusive. The reporting person undertakes to provide t…

  2. F2

    The reported shares are held by YD Biopharma Holding Limited, which is wholly owned by E820N Assets Ltd. (BVI), which is wholly owned by The E820N Trust (the "Trust"). Dr. Shen is the settlor, protect…

Original filing · 0001213900-26-098030
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

YDES